stockrow
Friday 6 November 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
19.19
0.30
+1.59%
Follow NAMS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 103 | 14 | 46 | 23 | 26 | (39.7%) | 25 | 120 | 308 | +139.1% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | — | 0 | 4 | (23) | (177) | (242) | (204) | (205) | n/m | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (22.04) | (1,255.57) | (530.25) | (905.74) | (789.94) | (905.7) pt | ||||||
| Net income | — | 0 | — | — | 0 | 4 | (23) | (177) | (242) | (204) | (205) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 5.41 | 0.17 | 0.48 | 0.19 | 0.21 | n/m | |||||
| Earnings | — | — | — | — | 0.01 | 1.21 | (1.19) | (2.15) | (2.56) | (1.72) | (1.69) | n/m | ||||||
| Cash flow | — | — | — | — | (0.16) | (0.04) | 0.56 | (1.72) | (1.68) | (1.25) | (1.21) | +50.7% | ||||||
| Capex | — | — | — | — | 0.00 | (0.01) | (0.01) | 0.00 | (0.01) | 0.00 | 0.00 | (12.9%) | ||||||
| Free cash flow | — | — | — | — | (0.16) | (0.05) | 0.55 | (1.72) | (1.69) | (1.25) | (1.22) | +49.9% | ||||||
| Book value | — | — | — | — | (3.39) | (1.84) | 22.68 | 3.51 | 8.03 | 5.77 | 5.08 | n/m | ||||||
| Shares, m | — | — | — | — | 3 | 3 | 19 | 82 | 94 | 118 | 122 | +107.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 43.24 | 53.22 | 184.61 | 91.08 | 70.3 | ||||||
| P/B | — | — | — | — | — | — | 0.49 | 3.40 | 3.20 | 6.08 | 3.75 | 3.3 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 28.25 | 34.91 | 156.28 | 66.59 | 54.9 | ||||||
| EV/FCF | — | — | — | — | — | — | (23.94) | (4.54) | (9.99) | (23.76) | (11.45) | (15.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | 0 | 11 | (141) | (159) | (148) | (150) | +212.0% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | (1) | 0 | 0 | +80.1% | ||||||
| Free cash flow | — | — | — | — | (1) | 0 | 10 | (141) | (159) | (148) | (151) | +210.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 2 | 1 | 442 | 297 | 756 | 590 | 615 | +224.8% | |||||
| Net debt | — | — | — | — | (1) | (1) | (468) | (340) | (834) | (638) | (635) | +241.9% | ||||||
| Shareholders’ equity | — | — | — | — | (11) | (6) | 430 | 288 | 758 | 683 | 631 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.03 | 2.99 | (7.32) | (42.86) | (39.88) | (24.95) | (27.79) | (25.0) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (307.51) | (23.13) | (307.5) pt | ||||||
| ROE | — | — | — | — | 0.07 | (49.46) | (10.68) | (49.25) | (46.20) | (28.29) | (30.16) | (28.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 4 | 3 | 17 | 29 | 68 | 100 | — | +90.4% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 6.04 | 0.49 | 0.67 | 0.23 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026
NewAmsterdam Pharma Company N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics Inc | $3.0B | 16.7× | 14.0× | +5.12% (above 0%: growing) | +46.67% (above 0%: growing) | +1,709.49% (above 0%: growing) | 70.81% | 48.02% | Compare |
| ZLAB Zai Lab Limited Unsponsored ADR | $2.6B | — (loss-making) | — (loss-making) | −6.79% (below 0%: shrinking) | n/m | −95.46% (below 0%: shrinking) | 0.00% | (58.20%) | Compare |
| XNCR Xencor, Inc. | $2.5B | — (loss-making) | — (loss-making) | +17.46% (above 0%: growing) | n/m | −52.91% (below 0%: shrinking) | 100.00% | (72.37%) | Compare |
| MBX MBX Biosciences, Inc. | $2.3B | — (loss-making) | — | — | n/m | −29.67% (below 0%: shrinking) | — | 0.00% | Compare |
| PHVS Pharvaris N.V. | $2.3B | — (loss-making) | — | — | n/m | −17.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | — (loss-making) | — (loss-making) | +5,406.90% (above 0%: growing) | n/m | −21.76% (below 0%: shrinking) | 100.00% | (230.58%) | |
| PVLA Palvella Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −99.09% (below 0%: shrinking) | n/m | −136.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | — (loss-making) | — (loss-making) | +258.49% (above 0%: growing) | n/m | +33.83% (above 0%: growing) | 45.85% | (663.95%) | Compare |
| Median of peers | $2.3B | — | — | −0.83% | — | −32.56% | 70.81% | (29.10%) |
NewAmsterdam Pharma Company N.V. (NAMS) Latest News
4 Nov
5 Aug
8 May
7 May
14 Feb
NAMS metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score